APOE4

Apolipoprotein E comes in three common variants, ε2, ε3, and ε4, and the version you carry shapes your risk for Alzheimer's disease, your cholesterol levels, and possibly how long you live. Researchers watch the ε4 allele most closely. It is the single largest common-variant genetic risk factor for late-onset Alzheimer's disease, and its effects span neurology, cardiovascular biology, and cellular fat metabolism.

Alzheimer's risk: a clear dose response

Carrying one copy of ε4 raises late-onset Alzheimer's risk meaningfully. Carrying two copies raises it dramatically. The foundational 1993 study by Corder and colleagues found that AD risk climbed from roughly 20% to roughly 90% as the number of ε4 alleles increased from zero to two, with average age of symptom onset dropping from around 84 to 68 years [1]. A subsequent meta-analysis put precise odds ratios on that gradient: compared with the most common ε3/ε3 genotype, ε3/ε4 carriers face roughly 3.2 times the odds of AD, while ε4/ε4 homozygotes face roughly 14.9 times the odds. The ε2/ε3 genotype sits at the other end, protective, with an odds ratio of approximately 0.6 [2].

Recent research from Fortea and colleagues in 2024 pushed the interpretation of homozygosity further. Using biomarker data, they found that ε4/ε4 individuals show abnormal amyloid markers from around age 55 and that most are amyloid-positive by 65. Clinical onset typically arrives around 65, a trajectory close enough to fully penetrant that the authors argue ε4/ε4 constitutes a distinct genetic form of AD rather than improved risk [3]. One caveat: the study was cross-sectional and drawn from research cohorts, which tend to over-represent people with family histories of dementia, so true population-level penetrance may be lower.

Lipids and cardiovascular disease

APOE genotype sets your baseline LDL cholesterol along a near-linear gradient, with ε2 carriers at the low end and ε4 carriers at the high end [4]. The cardiovascular story for ε4, however, is less alarming than the Alzheimer's story. A meta-analysis found ε4's coronary heart disease odds ratio at approximately 1.06, a small signal with a confidence interval that crosses 1.0, meaning it is not statistically firm [4]. The clearer contrast comes from ε2, which carries roughly 20% lower coronary heart disease risk (OR ~0.80) and, in UK Biobank data, LDL levels about 0.43 standard deviations lower than average [5].

The ε2 advantage: longevity beyond Alzheimer's

The ε2 allele's benefits extend past cholesterol. Data from human cohorts and apoE2 mouse models show that ε2 links to better survival independent of Alzheimer's pathology and cardiovascular factors; mice expressing human apoE2 showed approximately 10% longer median lifespan [6]. Kuo and colleagues found similar advantages in UK Biobank participants, confirming the lipid and coronary benefits in a large, population-based sample [5].

DHA and the APOE4 brain

APOE4 alters how the brain handles docosahexaenoic acid (DHA), the long-chain omega-3 fatty acid central to neuronal membrane function. Younger ε4 carriers show paradoxically greater regional DHA uptake on PET imaging [7], a finding that researchers interpret not as protection but as a compensatory response to disrupted metabolism. One proposed mechanism involves hyperactivation of cPLA2, an enzyme that funnels arachidonic acid through inflammatory pathways [8]. Whether DHA supplementation reverses any of this remains unclear: the PREVENT-E4 trial found that supplementation raised CSF DHA levels in ε4 carriers, but cognitive and structural endpoints were null [9]. Full discussion of the transport model and trial data lives in our companion piece on APOE4 and omega-3 brain transport.

Where the evidence is contested

The sharpest debate surrounds how to classify ε4/ε4 homozygosity. Fortea 2024 frames it as a near-fully-penetrant genetic condition comparable to familial AD, based on biomarker trajectories [3]. Critics, and the authors themselves, acknowledge that research cohort bias inflates apparent penetrance. Population-based estimates are not yet available. The practical stakes are high. If homozygosity is near-fully-penetrant, clinical management and genetic counseling for ε4/ε4 individuals should resemble that for known monogenic AD mutations. If penetrance is meaningfully lower in unselected populations, that framing could cause unnecessary distress. Resolving the question requires large prospective data in population-representative samples, which the field still awaits.

References

1. Corder 1993, Science — APOE4 gene dose & AD risk (dose-dependent) · PubMed 8346443
2. Farrer LA, Cupples LA, Haines JL et al. 1997 (JAMA) — 40-consortium meta-analysis; n=5,930 AD + 8,607 controls; ε2/ε3 OR 0.6 (0.5–0.8) for AD vs… · PubMed 9343467
3. Fortea 2024, Nat Med — APOE4/4 as a distinct genetic form of AD · PubMed 38710950
4. Bennet 2007, JAMA — APOE genotype, LDL & CHD meta-analysis · PubMed 17878422
5. Kuo CL et al. 2020 (Aging Albany NY) — UK Biobank PheWAS; n=379,703 European-descent, 9.4y follow-up; ε2/ε3: LDL −0.43 SD, CAD OR 0.87 (0.83–0.90),… · PubMed 32511104
6. Shinohara M et al. 2020 (eLife) — NACC (n=24,661; 5,413 deaths) + apoE-TR mouse survival cohort (n=118); APOE2 survival advantage persists after… · PubMed 33074098
7. Yassine HN et al. 2017 Alz Res Ther — DHA brain uptake PET ([1-¹¹C]-DHA); n=22; young APOE4 carriers: global GM K* +16% (p=0.04), posterior… · PubMed 28335828
8. Wang S, Yassine HN et al. 2022 Mol Neurodegen — cPLA2 hyperactivation in APOE4: p38 MAPK → cPLA2 → arachidonic acid extraction → LTB4 →… · PubMed 35705959
9. Yassine HN et al. 2026 (eBioMedicine) — PREVENT-E4 RCT peer-reviewed; n=368; 2g DHA/day × 24mo; primary: CSF DHA delivery … · PubMed 42315445